CJC-1295: The Complete 2026 Guide — Dosing, Benefits & Stacking with Ipamorelin

CJC-1295 is one of the most widely studied growth hormone-releasing hormone (GHRH) analogs in peptide research. Whether you're investigating its role in body composition, recovery, sleep quality, or aging, this guide covers everything the science currently supports — including how it compares between the DAC and no-DAC variants and how it stacks with Ipamorelin.

What Is CJC-1295?

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), a peptide naturally produced in the hypothalamus that signals the pituitary gland to produce and release growth hormone (GH). The original compound was modified to improve stability and extend half-life beyond the few minutes seen with native GHRH.

Two distinct versions exist:

• CJC-1295 with DAC (Drug Affinity Complex) — a version that covalently binds to albumin in the bloodstream, extending its half-life to 6–8 days.
• CJC-1295 without DAC (Modified GRF 1-29 / Mod GRF 1-29) — the shorter-acting version with a half-life of approximately 30 minutes, closely mimicking natural GHRH pulsatility.

Understanding which version you're dealing with is critical, as their pharmacokinetic profiles — and ideal use cases — differ substantially.

Mechanism of Action

CJC-1295 works by binding to GHRH receptors on somatotroph cells in the anterior pituitary gland. This binding triggers a cascade:

1. Activation of adenylyl cyclase and increased cyclic AMP (cAMP) production
2. Protein kinase A (PKA) phosphorylation cascades
3. Upregulation of growth hormone gene transcription and protein synthesis
4. Pulsatile release of GH into the bloodstream

Published clinical data (Baker et al., Journal of Clinical Endocrinology & Metabolism, 2006) showed that a single injection of CJC-1295 with DAC produced 2–10-fold increases in plasma GH lasting up to 6 days, with IGF-1 elevations of 0.5–3-fold persisting for 9–11 days.

CJC-1295 with DAC vs. Without DAC

The DAC modification attaches a reactive ester group that forms a covalent bond with lysine residues on serum albumin. This dramatically extends circulation time but fundamentally changes how the peptide behaves physiologically.

For those stacking with a GHRP like Ipamorelin, the no-DAC version is generally preferred because it creates discrete, synchronized GH pulses rather than a continuous background elevation.

Primary Research Benefits

1. Lean Muscle Mass and Body Composition

GH and IGF-1 elevation from CJC-1295 promotes nitrogen retention and protein synthesis in muscle tissue. Research subjects in clinical trials experienced meaningful increases in lean body mass over 12+ week periods. Body composition changes typically become observable at 4–8 weeks, with more substantial shifts requiring 3+ months of consistent use.

2. Fat Loss

Growth hormone has direct lipolytic effects — it stimulates fat cell (adipocyte) breakdown of stored triglycerides into free fatty acids. CJC-1295-driven GH elevation appears to preferentially reduce visceral and subcutaneous fat, particularly in the abdominal region. This effect is enhanced when CJC-1295 is combined with Ipamorelin, which provides complementary metabolic signaling.

3. Sleep Quality

One of the earliest reported effects in research subjects is improved sleep depth and duration, often noted within the first 1–2 weeks. Growth hormone secretion is strongly coupled to slow-wave (deep) sleep stages, and CJC-1295's GH-amplifying effects appear to reinforce this feedback loop. Many subjects report more restorative sleep as one of the most consistent early observations.

4. Recovery and Connective Tissue

GH and IGF-1 promote collagen synthesis, accelerate tissue repair, and support the healing of tendons, ligaments, and joints. CJC-1295's anabolic signaling environment supports faster recovery from training and injury. Research subject reports consistently include reduced muscle soreness and faster return to baseline after intense physical stress.

5. Anti-Aging and Cellular Maintenance

GH declines by approximately 14–15% per decade after age 30. CJC-1295's ability to restore more youthful GH pulsatility makes it of significant interest in longevity and age-related decline research. Observable benefits in older research populations include improvements in skin elasticity, bone density markers, and cognitive sharpness — though long-term human data remains limited.

CJC-1295 + Ipamorelin Stack

The CJC-1295/Ipamorelin combination is the most extensively discussed peptide stack in growth hormone research. Here's why it works:

• CJC-1295 acts on the GHRH receptor, amplifying the "amplitude" of GH pulses from the pituitary.
• Ipamorelin acts on the ghrelin/GHS-R1a receptor, providing a complementary "trigger" signal for GH release.

Used together, they activate two completely separate receptor pathways simultaneously, producing synergistic GH release that significantly exceeds either peptide alone. A key advantage of Ipamorelin specifically is its highly selective GH release profile — it does not meaningfully increase cortisol, prolactin, or ACTH at standard doses, keeping the hormonal side effect profile clean.

Standard Stack Protocol (Research Reference)

• CJC-1295 without DAC: 100–300 mcg per injection
• Ipamorelin: 100–300 mcg per injection
• Timing: Administered together, 30–60 minutes before sleep (or before training)
• Frequency: Once daily, up to 2–3x daily in some research protocols
• Cycle length: 8–12 weeks minimum for body composition research; some protocols extend to 6 months

The pre-sleep timing leverages the natural GH pulse that occurs during slow-wave sleep, amplifying it for enhanced recovery and anabolism.

Dosing Protocols

CJC-1295 without DAC (Mod GRF 1-29)

• Standard dose: 100–300 mcg per injection
• Frequency: 1–3x daily, timed around sleep and/or training
• Administration: Subcutaneous injection (abdomen, thigh)

CJC-1295 with DAC

• Standard dose: 1,000–2,000 mcg (1–2 mg) per injection
• Frequency: Once or twice weekly
• Administration: Subcutaneous injection

Both forms benefit from a 5-days-on/2-days-off cycling pattern in longer protocols to help preserve natural GHRH receptor sensitivity.

Side Effects and Safety Profile

Short-term clinical studies of CJC-1295 reported no serious adverse events. The safety profile is generally considered favorable at standard research doses. Common side effects include:

• Water retention: The most frequently reported effect, particularly in the hands, feet, and face. Usually transient and dose-dependent.
• Injection site reactions: Redness, mild swelling, or discomfort at the injection site. Common and typically short-lived.
• Facial flushing: Transient warmth or redness, typically occurring within minutes of injection and resolving quickly.
• Joint discomfort: Stiffness or mild achiness in joints, related to fluid dynamics and collagen turnover during elevated GH states.
• Headache: Occasionally reported, particularly at higher doses or early in a protocol.

The DAC variant carries a higher risk of cortisol and prolactin elevation due to its sustained receptor occupancy. The no-DAC variant stacked with Ipamorelin generally shows the cleanest side effect profile.

Reconstitution and Storage

Proper handling is essential to maintaining peptide potency:

Reconstitution

1. Use bacteriostatic water (BAC water) — typically 1–2 mL per vial
2. Inject the BAC water slowly along the inside wall of the vial — never directly onto the powder
3. Gently swirl to dissolve; never shake or vortex
4. Allow to fully dissolve before drawing

Storage

• Lyophilized powder: Store at 2–8°C (refrigerator); stable for 12–24 months when kept cold and dry
• Reconstituted solution: Store at 2–8°C; use within 28–30 days
• Avoid: Repeated freeze-thaw cycles, temperatures above 8°C post-reconstitution, and light exposure

Regulatory Status (2026)

CJC-1295 is not FDA-approved as a prescription drug. It was placed on the FDA's Category 2 bulk drug substances list, which restricted compounding pharmacy access. Key regulatory developments:

• In September 2024, the FDA announced CJC-1295 was being removed from Category 2 following nominators' withdrawal of submissions.
• In February 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 Category 2 peptides — including CJC-1295 — would be moved back to Category 1, restoring legal access through licensed compounding pharmacies with a valid physician's prescription.

Patients seeking CJC-1295 should work with licensed healthcare providers who can prescribe through compliant 503A or 503B compounding pharmacies.

Frequently Asked Questions

How long does CJC-1295 take to work?

Improved sleep quality is often the earliest reported effect, appearing within 1–2 weeks. Body composition changes typically emerge at 4–8 weeks. Full benefit assessment requires 3+ months of consistent use.

Is CJC-1295 the same as GHRH?

CJC-1295 is a synthetic analog of GHRH, not the identical molecule. It was engineered to resist enzymatic degradation and — in the DAC version — extend half-life dramatically. It binds the same receptor as native GHRH but with greater stability.

Should I use CJC-1295 with or without DAC?

For those stacking with Ipamorelin, the no-DAC variant is generally preferred due to its pulsatile profile and cleaner hormonal side effects. For simplicity and once-weekly dosing, the DAC variant may be considered but requires appropriate monitoring.

Can CJC-1295 be used alone?

Yes, though the synergistic effect with Ipamorelin is well-documented. Solo use of CJC-1295 produces meaningful GH elevation; adding Ipamorelin amplifies peak GH release by engaging a complementary receptor system.

Conclusion

CJC-1295 represents one of the most compelling GHRH analogs in current peptide research. Its ability to produce sustained, physiologically patterned growth hormone release — especially when combined with Ipamorelin — makes it a cornerstone of growth hormone optimization protocols. Whether you're investigating body composition, recovery, sleep quality, or healthy aging, the research foundation for CJC-1295 is among the strongest in the peptide space.

As with all research peptides, sourcing matters — seek out licensed compounding pharmacies working with physician oversight, and ensure products come with third-party purity verification.

Disclaimer: This article is for educational purposes only. CJC-1295 is a research compound. Consult a licensed healthcare provider before considering any peptide protocol.